Brian Abrahams
Stock Analyst at RBC Capital
(2.34)
# 2,624
Out of 5,147 analysts
447
Total ratings
46.22%
Success rate
-3.1%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $31 → $30 | $24.56 | +22.15% | 5 | Feb 26, 2026 | |
| GLPG Galapagos NV | Maintains: Sector Perform | $32 → $33 | $33.66 | -1.96% | 14 | Feb 25, 2026 | |
| PRTA Prothena Corporation | Maintains: Sector Perform | $11 → $12 | $8.67 | +38.41% | 13 | Feb 20, 2026 | |
| PTCT PTC Therapeutics | Maintains: Sector Perform | $87 → $82 | $68.19 | +20.25% | 24 | Feb 20, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Sector Perform | $10 → $12 | $17.51 | -31.47% | 4 | Feb 20, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $546 → $541 | $496.83 | +8.89% | 58 | Feb 13, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $180 → $177 | $132.25 | +33.84% | 25 | Feb 12, 2026 | |
| INCY Incyte | Maintains: Sector Perform | $95 → $92 | $101.27 | -9.15% | 25 | Feb 11, 2026 | |
| GILD Gilead Sciences | Maintains: Sector Perform | $103 → $118 | $148.95 | -20.78% | 35 | Feb 11, 2026 | |
| BIIB Biogen | Maintains: Outperform | $217 → $233 | $191.82 | +21.47% | 42 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $13 | $8.75 | +48.57% | 20 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $30 | $15.97 | +87.85% | 1 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $40 | $14.85 | +169.36% | 2 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $36 | $17.45 | +106.30% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $70 → $83 | $70.00 | +18.57% | 3 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $103 | $91.35 | +12.75% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $36.54 | -34.32% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $7 | $3.49 | +100.57% | 7 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $15.34 | +43.42% | 6 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $12.49 | +44.12% | 5 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $53 | $8.57 | +518.44% | 9 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $1.5 → $1 | $0.96 | +4.19% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $3 → $2 | $1.30 | +53.85% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $58 | $43.23 | +34.17% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $19 | $9.41 | +101.91% | 13 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $704 → $708 | $781.67 | -9.42% | 35 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $23 | $16.76 | +37.23% | 35 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $84 | $19.00 | +342.11% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $163.89 | -12.75% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $35.46 | +12.80% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $14.30 | +4.90% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $3.63 | +147.93% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $23.39 | - | 4 | Dec 4, 2017 |
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Outperform
Price Target: $31 → $30
Current: $24.56
Upside: +22.15%
Galapagos NV
Feb 25, 2026
Maintains: Sector Perform
Price Target: $32 → $33
Current: $33.66
Upside: -1.96%
Prothena Corporation
Feb 20, 2026
Maintains: Sector Perform
Price Target: $11 → $12
Current: $8.67
Upside: +38.41%
PTC Therapeutics
Feb 20, 2026
Maintains: Sector Perform
Price Target: $87 → $82
Current: $68.19
Upside: +20.25%
MoonLake Immunotherapeutics
Feb 20, 2026
Maintains: Sector Perform
Price Target: $10 → $12
Current: $17.51
Upside: -31.47%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Outperform
Price Target: $546 → $541
Current: $496.83
Upside: +8.89%
Neurocrine Biosciences
Feb 12, 2026
Maintains: Outperform
Price Target: $180 → $177
Current: $132.25
Upside: +33.84%
Incyte
Feb 11, 2026
Maintains: Sector Perform
Price Target: $95 → $92
Current: $101.27
Upside: -9.15%
Gilead Sciences
Feb 11, 2026
Maintains: Sector Perform
Price Target: $103 → $118
Current: $148.95
Upside: -20.78%
Biogen
Feb 9, 2026
Maintains: Outperform
Price Target: $217 → $233
Current: $191.82
Upside: +21.47%
Jan 30, 2026
Maintains: Outperform
Price Target: $14 → $13
Current: $8.75
Upside: +48.57%
Jan 29, 2026
Maintains: Outperform
Price Target: $28 → $30
Current: $15.97
Upside: +87.85%
Jan 23, 2026
Maintains: Outperform
Price Target: $33 → $40
Current: $14.85
Upside: +169.36%
Jan 23, 2026
Maintains: Outperform
Price Target: $20 → $36
Current: $17.45
Upside: +106.30%
Jan 22, 2026
Downgrades: Sector Perform
Price Target: $70 → $83
Current: $70.00
Upside: +18.57%
Dec 16, 2025
Maintains: Outperform
Price Target: $70 → $103
Current: $91.35
Upside: +12.75%
Dec 1, 2025
Downgrades: Underperform
Price Target: $24
Current: $36.54
Upside: -34.32%
Dec 1, 2025
Upgrades: Outperform
Price Target: $4 → $7
Current: $3.49
Upside: +100.57%
Nov 21, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $15.34
Upside: +43.42%
Nov 14, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $12.49
Upside: +44.12%
Nov 13, 2025
Maintains: Outperform
Price Target: $55 → $53
Current: $8.57
Upside: +518.44%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $1.5 → $1
Current: $0.96
Upside: +4.19%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $3 → $2
Current: $1.30
Upside: +53.85%
Nov 4, 2025
Maintains: Outperform
Price Target: $55 → $58
Current: $43.23
Upside: +34.17%
Nov 4, 2025
Maintains: Outperform
Price Target: $30 → $19
Current: $9.41
Upside: +101.91%
Oct 29, 2025
Maintains: Sector Perform
Price Target: $704 → $708
Current: $781.67
Upside: -9.42%
Jul 17, 2025
Maintains: Sector Perform
Price Target: $25 → $23
Current: $16.76
Upside: +37.23%
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $19.00
Upside: +342.11%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $163.89
Upside: -12.75%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $35.46
Upside: +12.80%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $14.30
Upside: +4.90%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $3.63
Upside: +147.93%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $23.39
Upside: -